Inventiva (NASDAQ:IVA) Coverage Initiated at Cantor Fitzgerald

Equities research analysts at Cantor Fitzgerald started coverage on shares of Inventiva (NASDAQ:IVA) in a research report issued to clients and investors on Friday, MarketBeat.com reports. The firm set an “overweight” rating on the stock.

Several other research analysts also recently issued reports on IVA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a report on Tuesday, April 21st. Wall Street Zen downgraded Inventiva from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Truist Financial assumed coverage on Inventiva in a research report on Thursday, March 19th. They set a “buy” rating and a $13.00 price objective on the stock. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $16.56.

Inventiva Price Performance

Shares of NASDAQ:IVA opened at $4.62 on Friday. The firm has a 50 day simple moving average of $4.36 and a 200 day simple moving average of $5.32. Inventiva has a one year low of $2.85 and a one year high of $7.98.

Institutional Investors Weigh In On Inventiva

A number of institutional investors have recently added to or reduced their stakes in IVA. Creative Planning acquired a new position in Inventiva in the 2nd quarter valued at approximately $32,000. Millennium Management LLC acquired a new position in shares of Inventiva during the third quarter worth $649,000. NewEdge Advisors LLC bought a new stake in shares of Inventiva in the third quarter worth $116,000. UBS Group AG grew its stake in shares of Inventiva by 28,881.6% in the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after purchasing an additional 2,634,580 shares during the last quarter. Finally, Simplify Asset Management Inc. acquired a new stake in Inventiva in the fourth quarter valued at $1,570,000. 19.06% of the stock is owned by institutional investors.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.